Soligenix Demonstrates Extended Heat Stability in Filovirus Vaccine Platform

Soligenix Inc. has published a peer-reviewed summary of new scientific data demonstrating long-term high-temperature stability of its protein subunit vaccine platform designed for Ebola and Marburg-related viruses. The company has been developing formulations intended to remain stable even when stored for extended periods at temperatures above 40°C, a capability that could transform global outbreak response readiness. The publication, titled 'Development of Thermostable Filovirus Vaccines Using Protein Subunit Technology,' outlines preclinical data showing that the company's filovirus vaccine antigens, formulated with its proprietary ThermoVax platform, maintained structural integrity and immunogenicity after 12 months of storage at 40°C.

The same formulation also outperformed unstabilized comparators that degraded significantly under identical conditions. Most recently, this stability window was increased to at least 2 years at 40°C. The publication expands earlier work funded through ongoing U.S. government contracts with BARDA and the National Institute of Allergy and Infectious Diseases. This extended stability represents a significant advancement for vaccine distribution in tropical climates and resource-limited settings where reliable cold chain infrastructure is often unavailable.

The development of Soligenix's vaccine programs incorporates the use of its proprietary heat stabilization platform technology, known as ThermoVax. To date, this business segment has been supported with government grants and contract funding from the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency and the Biomedical Advanced Research and Development Authority. The company's Public Health Solutions business segment includes development programs for RiVax, its ricin toxin vaccine candidate, as well as its vaccine programs targeting filoviruses and CiVax, the company's vaccine candidate for the prevention of COVID-19.

The ability to maintain vaccine stability at elevated temperatures for extended periods addresses one of the most significant challenges in global vaccine distribution. Traditional vaccines typically require strict cold chain maintenance from manufacturing to administration, creating logistical barriers and increased costs in remote or underdeveloped regions. Soligenix's technology could enable stockpiling of vaccines for emergency response without the need for expensive refrigeration infrastructure. This advancement comes at a critical time when global health organizations are prioritizing preparedness for future pandemic threats and biodefense scenarios.

The full scientific article discussing these findings can be accessed at https://ibn.fm/EkiE7. Additional information about the company's research and development programs is available through their corporate website at https://www.Soligenix.com. The latest updates and news relating to the company's progress are maintained in their newsroom at https://ibn.fm/SNGX. These developments in thermostable vaccine technology represent a meaningful step forward in addressing global health security challenges, particularly in regions most vulnerable to infectious disease outbreaks.